Emerging infection and sepsis biomarkers: will they change current therapies?

References

• Kissoon N, Carcillo JA, Espinosa V, et al. World federation of pediatric intensive care and critical care societies: global sepsis initiative. Pediatr Crit Care Med. 2011;12(5):494–503.
   PubMed Web of Science ®Google Scholar
• Gaieski DF, Edwards JM, Kallan MJ, et al. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41(5):1167–1174.
   PubMed Web of Science ®Google Scholar
• Kaukonen K-M, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. Jama. 2014;311(13):1308–1316.
   PubMed Web of Science ®Google Scholar
• Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–1310.
   PubMed Web of Science ®Google Scholar
• Torio CA, Andrews RA. Agency for healthcare research and quality, healthcare cost and utilization project, statistical brief #160. 2013. [cited 2016 Aug 11]. Available from: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb160.jsp.
   Google Scholar
• Bone, R.C., et al. American College of chest physicians/society of critical care medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):964–974.
   Google Scholar
• Levy, M.M., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Medicine. 2003;29:530–538.
   PubMedGoogle Scholar
• Singer, M., et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). Jama. 2016;315(8):801–810.
   PubMed Web of Science ®Google Scholar
• Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock. 2001;16(2):83–96.
   PubMed Web of Science ®Google Scholar
• Aziz M, Jacob A, Yang W-L, et al. Current trends in inflammatory and immunomodulatory mediators in sepsis. J Leukoc Biol. 2013;93(3):329–342.
   PubMed Web of Science ®Google Scholar
• Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8(10):776–787.
   PubMed Web of Science ®Google Scholar
• Hoesel LM, Neff TA, Neff SB, et al. Harmful and protective roles of neutrophils in sepsis. Shock. 2005;24(1):40–47.
   PubMed Web of Science ®Google Scholar
• Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117(4):1162–1172.
   PubMed Web of Science ®Google Scholar
• Fisher CJ Jr., Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: fcfusion protein. The soluble TNF receptor sepsis study group. N Engl J Med. 1996;334(26):1697–1702.
   PubMed Web of Science ®Google Scholar
• Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb sepsis study group. Jama. 1995;273(12):934–941.
   PubMed Web of Science ®Google Scholar
• Bone RC, Fisher CJ, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317(11):653–658.
   PubMed Web of Science ®Google Scholar
• Fisher CJ Jr., Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994;22(1):12–21.
   PubMed Web of Science ®Google Scholar
• Ziegler EJ, Fisher CJ, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A sepsis study group. N Engl J Med. 1991;324(7):429–436.
   PubMed Web of Science ®Google Scholar
• Eskandari MK, Bolgos G, Miller C, et al. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol. 1992;148(9):2724–2730.
   PubMed Web of Science ®Google Scholar
• Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med. 1997;25(7):1095–1100.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Karl IE, The pathophysiology and treatment of sepsis. N Engl J Med, 2003. 348(2): p. 138–150.
   PubMed Web of Science ®Google Scholar
• Hutchins NA, Unsinger J, Hotchkiss RS, et al. The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med. 2014;20(4):224–233.
   PubMed Web of Science ®Google Scholar
• Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420(6917):885–891.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol. 2001;166(11):6952–6963.
   PubMed Web of Science ®Google Scholar
• Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. Jama. 2011;306(23):2594–2605.
   PubMed Web of Science ®Google Scholar
• Group BDW. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;37:2290–2298.
   Google Scholar
• Puntmann VO. How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgrad Med J. 2009;85(1008):538–545.
   PubMed Web of Science ®Google Scholar
• Marshall JC, Reinhart K, International Sepsis F. Biomarkers of sepsis. Crit Care Med. 2009;37(7):2290–2298.
   PubMed Web of Science ®Google Scholar
• Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med. 2011;12(2):165–173.
   PubMed Web of Science ®Google Scholar
• Wong, H.R., et al. The pediatric sepsis biomarker risk model. Crit Care. 2012;16(5):R174.
   PubMed Web of Science ®Google Scholar
• Dupuy, A.M., et al. Role of biomarkers in the management of antibiotic therapy: an expert panel review: I - currently available biomarkers for clinical use in acute infections. Ann Intensive Care. 2013;3(1):22.
   PubMed Web of Science ®Google Scholar
• Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36(3):941–952.
   PubMed Web of Science ®Google Scholar
• Standage SW, Wong HR. Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther. 2011;9(1):71–79.
   PubMed Web of Science ®Google Scholar
• Wojno ED, Hunter CA. New directions in the basic and translational biology of interleukin-27. Trends Immunol. 2012;33(2):91–97.
   PubMed Web of Science ®Google Scholar
• Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002;16(6):779–790.
   PubMed Web of Science ®Google Scholar
• Ulla, M., et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care. 2013;17(4):R168.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu D, Liu Y-N, et al. The accuracy of presepsin (sCD14-ST) for the diagnosis of sepsis in adults: a meta-analysis. Crit Care. 2015;19:323.
   PubMed Web of Science ®Google Scholar
• Samraj RS, Zingarelli B, Wong HR. Role of biomarkers in sepsis care. Shock. 2013;40(5):358–365.
   PubMed Web of Science ®Google Scholar
• Wagner C, Deppisch R, Denefleh B, et al. Expression patterns of the lipopolysaccharide receptor CD14, and the FCgamma receptors CD16 and CD64 on polymorphonuclear neutrophils: data from patients with severe bacterial infections and lipopolysaccharide-exposed cells. Shock. 2003;19(1):5–12.
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–1665.
   PubMed Web of Science ®Google Scholar
• Forsblom E, Aittoniemi J, Ruotsalainen E, et al. High cell-free DNA predicts fatal outcome among Staphylococcus aureus bacteraemia patients with intensive care unit treatment. PLoS One. 2014;9(2):e87741.
   PubMed Web of Science ®Google Scholar
• Sweeney, T.E., et al. A comprehensive time-course-based multicohort analysis of sepsis and sterile inflammation reveals a robust diagnostic gene set. Sci Transl Med. 2015;7(287):287ra71.
   PubMed Web of Science ®Google Scholar
• Wong HR, Weiss SL, Giuliano JS, et al. The temporal version of the pediatric sepsis biomarker risk model. PLoS One. 2014;9(3):e92121.
   PubMed Web of Science ®Google Scholar
• Wong HR, Cvijanovich NZ, Anas N, et al. Prospective testing and redesign of a temporal biomarker based risk model for patients with septic shock: implications for septic shock biology. EBioMedicine. 2015;2(12):2087–2093.
   PubMed Web of Science ®Google Scholar
• Wong HR, Cvijanovich NZ, Anas N, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med. 2015;191(3):309–315. .
   PubMed Web of Science ®Google Scholar
• Gibot S, Béné MC, Noel R, et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med. 2012;186(1):65–71.
   PubMed Web of Science ®Google Scholar
• Becker KL, Nylén ES, White JC, et al. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004;89(4):1512–1525.
   PubMed Web of Science ®Google Scholar
• Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol. 2010;48(7):2325–2329.
   PubMed Web of Science ®Google Scholar
• Arkader R, Troster EJ, Lopes MR, et al. Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child. 2006;91(2):117–120.
   PubMed Web of Science ®Google Scholar
• Rey C, Los Arcos M, Concha A, et al. Procalcitonin and C-reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children. Intensive Care Med. 2007;33(3):477–484.
   PubMed Web of Science ®Google Scholar
• Simon L, Saint-Louis P, Amre DK, et al. Procalcitonin and C-reactive protein as markers of bacterial infection in critically ill children at onset of systemic inflammatory response syndrome. Pediatr Crit Care Med. 2008;9(4):407–413.
   PubMed Web of Science ®Google Scholar
• Brunkhorst FM, Eberhard OK, Brunkhorst R. Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med. 1999;27(10):2172–2176.
   PubMed Web of Science ®Google Scholar
• Uzzan, B., et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34(7):1996–2003.
   PubMed Web of Science ®Google Scholar
• Hunziker S, Hügle T, Schuchardt K, et al. The value of serum procalcitonin level for differentiation of infectious from noninfectious causes of fever after orthopaedic surgery. J Bone Joint Surg Am. 2010;92(1):138–148.
   PubMed Web of Science ®Google Scholar
• Sponholz C, Sakr Y, Reinhart K, et al. Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature. Crit Care. 2006;10(5):R145.
   PubMed Web of Science ®Google Scholar
• Tang BMP, Eslick GD, Craig JC, et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis. 2007;7(3):210–217.
   PubMed Web of Science ®Google Scholar
• Hatherill M, Tibby SM, Turner C, et al. Procalcitonin and cytokine levels: relationship to organ failure and mortality in pediatric septic shock. Crit Care Med. 2000;28(7):2591–2594.
   PubMed Web of Science ®Google Scholar
• Boussekey N, Leroy O, Georges H, et al. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection. 2005;33(4):257–263.
   PubMed Web of Science ®Google Scholar
• Han YY, Doughty LA, Kofos D, et al. Procalcitonin is persistently increased among children with poor outcome from bacterial sepsis. Pediatr Crit Care Med. 2003;4(1):21–25.
   PubMedGoogle Scholar
• Wanner GA, Keel M, Steckholzer U, et al. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med. 2000;28(4):950–957.
   PubMed Web of Science ®Google Scholar
• Nobre V, Harbarth S, Graf J-D, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177(5):498–505.
   PubMed Web of Science ®Google Scholar
• Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg. 2009;394(2):221–226.
   PubMed Web of Science ®Google Scholar
• Hochreiter M, Köhler T, Schweiger A, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care. 2009;13(3):R83.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. Jama. 2009;302(10):1059–1066.
   PubMed Web of Science ®Google Scholar
• Bouadma L, Luyt C-E, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463–474.
   PubMed Web of Science ®Google Scholar
• Prkno, A., et al. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock–a systematic review and meta-analysis. Crit Care. 2013;17(6):R291.
   PubMed Web of Science ®Google Scholar
• De Jong, E., et al., Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis, 2016.
   Google Scholar
• Lam SW, Bauer SR, Duggal A. Procalcitonin-based algorithms to initiate or stop antibiotic therapy in critically ill patients: is it time to rethink our strategy? Int J Antimicrob Agents. 2016;47(1):20–27.
   PubMed Web of Science ®Google Scholar
• Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011;39(9):2048–2058.
   PubMed Web of Science ®Google Scholar
• Shehabi Y, Sterba M, Garrett PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med. 2014;190(10):1102–1110.
   PubMed Web of Science ®Google Scholar
• Quenot, J.P., et al. Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy. Ann Intensive Care. 2013;3(1):21.
   PubMed Web of Science ®Google Scholar
• Awasthi A, Carrier Y, Peron JPS, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol. 2007;8(12):1380–1389.
   PubMed Web of Science ®Google Scholar
• Stumhofer JS, Silver JS, Laurence A, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol. 2007;8(12):1363–1371.
   PubMed Web of Science ®Google Scholar
• Wong HR, Cvijanovich NZ, Hall M, et al. Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children. Crit Care. 2012;16(5):R213. .
   PubMed Web of Science ®Google Scholar
• Hanna WJ, Berrens Z, Langner T, et al. Interleukin-27: a novel biomarker in predicting bacterial infection among the critically ill. Crit Care. 2015;19:378.
   PubMed Web of Science ®Google Scholar
• Wong HR, Lindsell CJ, Lahni P, et al. Interleukin 27 as a sepsis diagnostic biomarker in critically ill adults. Shock. 2013;40(5):382–386.
   PubMed Web of Science ®Google Scholar
• Wong HR, Liu KD, Kangelaris KN, et al. Performance of interleukin-27 as a sepsis diagnostic biomarker in critically ill adults. J Crit Care. 2014;29(5):718–722.
   PubMed Web of Science ®Google Scholar
• Krumbiegel D, Anthogalidis-Voss C, Markus H, et al. Enhanced expression of IL-27 mRNA in human newborns. Pediatr Allergy Immunol. 2008;19(6):513–516.
   PubMed Web of Science ®Google Scholar
• Meyer CU, Birkholz J, Weins N, et al. Dendritic cells change IL-27 production pattern during childhood. BMC Res Notes. 2015;8:232.
   PubMedGoogle Scholar
• Kraft JD, Horzempa J, Davis C, et al. Neonatal macrophages express elevated levels of interleukin-27 that oppose immune responses. Immunology. 2013;139(4):484–493.
   PubMed Web of Science ®Google Scholar
• Camussi G, Mariano F, Biancone L, et al. Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide. J Immunol. 1995;155(1):316–324.
   PubMed Web of Science ®Google Scholar
• Chenevier-Gobeaux C, Bardet V, Poupet H, et al. Presepsin (sCD14-ST) secretion and kinetics by peripheral blood mononuclear cells and monocytic THP-1 cell line. Ann Biol Clin (Paris). 2016;74(1):93–97.
   PubMed Web of Science ®Google Scholar
• Nakamura, M., et al. Early elevation of plasma soluble CD14 subtype, a novel biomarker for sepsis, in a rabbit cecal ligation and puncture model. Crit Care. 2008;12(2):P194.
   Google Scholar
• Shozushima T, Takahashi G, Matsumoto N, et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011;17(6):764–769.
   PubMed Web of Science ®Google Scholar
• Behnes, M., et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care. 2014;18(5):507.
   PubMed Web of Science ®Google Scholar
• Masson, S., et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian outcome sepsis trial. Crit Care. 2014;18(1):R6.
   PubMed Web of Science ®Google Scholar
• Endo S, Suzuki Y, Takahashi G, et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: a multicenter prospective study. J Infect Chemother. 2014;20(1):30–34.
   PubMed Web of Science ®Google Scholar
• Shirakawa K, Naitou K, Hirose J, et al. Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients. Clin Chem Lab Med. 2011;49(5):937–939.
   PubMed Web of Science ®Google Scholar
• Kurihara T, Yanagida A, Yokoi H, et al. Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST. Anal Biochem. 2008;375(1):144–146.
   PubMed Web of Science ®Google Scholar
• Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta. 2011;412(23-24:2157–2161.
   Web of Science ®Google Scholar
• Ng PC, Lam HS. Diagnostic markers for neonatal sepsis. Curr Opin Pediatr. 2006;18(2):125–131.
   PubMed Web of Science ®Google Scholar
• Wang X, Li Z-Y, Zeng L, et al. Neutrophil CD64 expression as a diagnostic marker for sepsis in adult patients: a meta-analysis. Crit Care. 2015;19:245.
   PubMed Web of Science ®Google Scholar
• Cid J, Aguinaco R, Sánchez R, et al. Neutrophil CD64 expression as marker of bacterial infection: a systematic review and meta-analysis. J Infect. 2010;60(5):313–319.
   PubMed Web of Science ®Google Scholar
• Dimoula A, Pradier O, Kassengera Z, et al. Serial determinations of neutrophil CD64 expression for the diagnosis and monitoring of sepsis in critically ill patients. Clin Infect Dis. 2014;58(6):820–829.
   PubMed Web of Science ®Google Scholar
• Icardi M, Erickson Y, Kilborn S, et al. CD64 index provides simple and predictive testing for detection and monitoring of sepsis and bacterial infection in hospital patients. J Clin Microbiol. 2009;47(12):3914–3919.
   PubMed Web of Science ®Google Scholar
• Livaditi O, Kotanidou A, Psarra A, et al. Neutrophil CD64 expression and serum IL-8: sensitive early markers of severity and outcome in sepsis. Cytokine. 2006;36(5–6):283–290.
   PubMed Web of Science ®Google Scholar
• Wong HR, Shanley TP, Sakthivel B, et al. Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol Genomics. 2007;30(2):146–155.
   PubMed Web of Science ®Google Scholar
• Wong HR, Cvijanovich N, Wheeler DS, et al. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med. 2008;178(3):276–282.
   PubMed Web of Science ®Google Scholar
• Kraft R, Herndon DN, Finnerty CC, et al. Predictive value of IL-8 for sepsis and severe infections after burn injury: a clinical study. Shock. 2015;43(3):222–227.
   PubMed Web of Science ®Google Scholar
• Calfee CS, Thompson BT, Parsons PE, et al. Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock. Crit Care Med. 2010;38(6):1436–1441.
   PubMed Web of Science ®Google Scholar
• Zeerleder S, Zwart B, Wuillemin WA, et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med. 2003;31(7):1947–1951.
   PubMed Web of Science ®Google Scholar
• Hamaguchi, S., et al. Origin of circulating free DNA in sepsis: analysis of the CLP mouse model. Mediators Inflamm. 2015;2015:614518.
   PubMed Web of Science ®Google Scholar
• Moreira, V.G., et al. Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. Ann Clin Biochem. 2010;47(Pt(3)):253–258.
   Web of Science ®Google Scholar
• Huttunen R, Kuparinen T, Jylhävä J, et al. Fatal outcome in bacteremia is characterized by high plasma cell free DNA concentration and apoptotic DNA fragmentation: a prospective cohort study. PLoS One. 2011;6(7):e21700.
   Google Scholar
• Dwivedi DJ, Toltl LJ, Swystun LL, et al. Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Crit Care. 2012;16(4):R151.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Wort SJ, Thomas H, et al. Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patients. Crit Care. 2006;10(2):R60.
   PubMed Web of Science ®Google Scholar
• Saukkonen K, Lakkisto P, Varpula M, et al. Association of cell-free plasma DNA with hospital mortality and organ dysfunction in intensive care unit patients. Intensive Care Med. 2007;33(9):1624–1627.
   PubMed Web of Science ®Google Scholar
• Yang J, Selvaganapathy PR, Gould TJ, et al. A microfluidic device for rapid quantification of cell-free DNA in patients with severe sepsis. Lab Chip. 2015;15(19):3925–3933.
   PubMed Web of Science ®Google Scholar
• Sweeney T, Wong H, Khatri P, Robust classification of bacterial and viral infections via integrated host gene expression diagnostics. Sci Transl Med. 2016;8:346ra91–346ra91. In press
   PubMed Web of Science ®Google Scholar
• Cvijanovich N, Shanley TP, Lin R, et al. Validating the genomic signature of pediatric septic shock. Physiol Genomics. 2008;34(1):127–134.
   PubMed Web of Science ®Google Scholar
• Wong HR, Cvijanovich N, Allen GL, et al. Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Crit Care Med. 2009;37(5):1558–1566.
   PubMed Web of Science ®Google Scholar
• Wong HR. Genetics and genomics in pediatric septic shock. Crit Care Med. 2012;40(5):1618–1626.
   PubMed Web of Science ®Google Scholar
• Wong HR, Walley KR, Pettilä V, et al. Comparing the prognostic performance of ASSIST to interleukin-6 and procalcitonin in patients with severe sepsis or septic shock. Biomarkers. 2015;20(2):132–135.
   PubMed Web of Science ®Google Scholar
• Wong HR, Lindsell CJ, Pettilä V, et al. A multibiomarker-based outcome risk stratification model for adult septic shock. Crit Care Med. 2014;42(4):781–789.
   PubMed Web of Science ®Google Scholar
• Wong, H., et al. PERSEVERE-II: redefining the pediatric sepsis biomarker risk model with septic shock phenotype. Crit Care Med. Forthcoming 2016.
   Google Scholar
• Wong HR, Cvijanovich N, Lin R, et al. Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med. 2009;7:34.
   PubMed Web of Science ®Google Scholar
• Wong HR, Cvijanovich NZ, Allen GL, et al. Validation of a gene expression-based subclassification strategy for pediatric septic shock. Crit Care Med. 2011;39(11):2511–2517.
   PubMed Web of Science ®Google Scholar
• Wong HR, Wheeler DS, Tegtmeyer K, et al. Toward a clinically feasible gene expression-based subclassification strategy for septic shock: proof of concept. Crit Care Med. 2010;38(10):1955–1961.
   PubMed Web of Science ®Google Scholar
• Wong HR, Atkinson SJ, Cvijanovich NZ, et al. Combining prognostic and predictive enrichment strategies to identify children with septic shock responsive to corticosteroids. Crit Care Med. 2016;1. PMID:27270179 [Epub ahead of print].
   Google Scholar
• Sandquist M, Wong HR. Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment. Expert Rev Clin Immunol. 2014;10(10):1349–1356.
   PubMed Web of Science ®Google Scholar
• Davenport EE, Burnham KL, Radhakrishnan J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016;4(4):259–271.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242.
   PubMed Web of Science ®Google Scholar
• Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. Immunology. 2010;129(4):474–481.
   PubMed Web of Science ®Google Scholar
• Shao, R., et al. Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit Care. 2016;20(1):124.
   PubMed Web of Science ®Google Scholar
• Guignant, C., et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care. 2011;15(2):R99.
   PubMed Web of Science ®Google Scholar
• Chang, K., et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care. 2014;18(1):R3.
   PubMed Web of Science ®Google Scholar
• Huang X, Venet F, Wang YL, et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A. 2009;106(15):6303–6308.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhou Y, Lou J, et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care. 2010;14(6):R220.
   PubMed Web of Science ®Google Scholar
• Huang X, Chen Y, Chung C-S, et al. Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis. J Immunol. 2014;192(3):1091–1099.
   PubMed Web of Science ®Google Scholar
• Brahmamdam P, Inoue S, Unsinger J, et al. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88(2):233–240.
   PubMed Web of Science ®Google Scholar